Loay Kassem: Impact of BRCA Mutations on ER+ Breast Cancer Treatment
Loay Kassem, Assistant Professor of Clinical Oncology at Kasr AlAiny School of Medicine, shared a post on LinkedIn:
“We know a lot about BRCA mutations in Triple negative breast cancer.
In ER-positive disease, this is totally a different story.
We are not sure if they respond well to hormonal therapies and CDK4/6 inhibitors. That’s why we needed to do this study.
I am proud to have participated in this publication with a great team of researchers led by a great efforts of prof Hamdy Azim and prof Hagar ElGhazawy and my dear friends Kyrillus Shohdy, Shaimaa Lasheen, Dalia ElNasser Awad
We studied data of 34,960 patients from 22 studies.
In both the early and metastatic setting, BRCA1/2 mutant ER+ patients were associated with a worse DFS (or PFS) and worse OS compared to BRCA wild-type even when CDK4/6 inhibitors are used.
By looking into the individual-patient data, the poorer prognosis is mostly driven by BRCA2 mutations and can be explained by the co-occurrence of RB1 Alterations.
So, my question to you,
In a high risk patient with early ER+/HER2- and BRCA mutation, would you give adjuvant CDK4/6 or Olaparib?”
Title: Impact of BRCA Mutation on Treatment Outcomes of Endocrine Therapy ± CDK4/6 Inhibitors in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor-2–Negative Breast Cancer: A Systematic Review and Meta-Analysis
Authors: Hamdy A. Azim, Hagar Elghazawy, Kyrillus S. Shohdy, Shaimaa Lasheen, Mahmoud Elghazawy, Ramy Mohamed Ghazy, Dalia Abdelnasser, Loay Kassem
More posts Featuring Load Kassem on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023